Results 21 to 30 of about 662,207 (147)

The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study

Medicines, 2022
Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial.
Suriyon Uitrakul, Krittika Aksonnam, Pimchanok Srivichai, Sorawit Wicheannarat, Supatcha Incomenoy   +4 more
doaj   +1 more source

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity

Frontiers in Endocrinology, 2018
The EMPA-REG OUTCOME study revealed that a sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, can remarkably reduce cardiovascular (CV) mortality and heart failure in patients with high-risk type 2 diabetes.
Ningning Wan, Asadur Rahman, Hirofumi Hitomi, Akira Nishiyama   +3 more
doaj   +1 more source

Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database

Endocrine Journal, 2023
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of antidiabetic drugs. Guidelines for the proper use of SGLT2 inhibitors recommend caution regarding urinary tract infections (UTIs).
Go Anan, Daisuke Kikuchi, Kenji Omae, Takuo Hirose, Kouji Okada, Takefumi Mori   +5 more
doaj   +1 more source

Empagliflozin: the latest SGLT2 inhibitor on the block [PDF]

, 2016
Empagliflozin, the latest SGLT2 inhibitor is a selective, highly potent and competitive inhibitor of SGLT2 leading to the lowering of plasma glucose level by letting the sugar pass in the urine.
Ahluwalia, Kaza, Bhanwra, Sangeeta
core   +1 more source

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients

Cardiovascular Diabetology, 2020
Background Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown greater reductions of cardiovascular event risks than dipeptidyl peptidase-4 (DPP4) inhibitors, whereby possible mechanisms may involve the better pleiotropic effects of SGLT2 ...
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai   +7 more
doaj   +1 more source

Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors [PDF]

Diabetes & Metabolism Journal, 2019
BackgroundWe investigated the predictive markers for the therapeutic efficacy and the best combination of sodium-glucose co-transporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and ipragliflozin) therapy in patients with type 2 diabetes ...
Ji-Yeon Lee, Yongin Cho, Minyoung Lee, You Jin Kim, Yong-ho Lee, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang   +7 more
doaj   +1 more source

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?

Cardiovascular Diabetology, 2020
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF).
Atsushi Tanaka, Koichi Node
doaj   +1 more source

Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use

Endocrine Connections, 2020
Background and Aims: It is currently unclear whether sodium–glucose co-transporter 2 (SGLT2) inhibitor administration can improve the insulin sensitivity as well as rapidly reduce plasma glucose concentrations in humans during the early phase of ...
Yuka Goto, Yoshie Otsuka, Kenji Ashida, Ayako Nagayama, Nao Hasuzawa, Shimpei Iwata, Kento Hara, Munehisa Tsuruta, Nobuhiko Wada, Seiichi Motomura, Yuji Tajiri, Masatoshi Nomura   +11 more
doaj   +1 more source

Renoprotective potential of concomittant medications with SGLT2 inhibitors and renin-angiotensin system inhibitors in diabetic nephropathy without albuminuria: a retrospective cohort study

Scientific Reports, 2023
The renal protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors and renin-angiotensin system (RAS) inhibitors on diabetic nephropathy without albuminuria have not been fully investigated.
Tatsuya Ishibashi, Shuhei Morita, Hiroto Furuta, Masahiro Nishi, Taka-Aki Matsuoka   +4 more
doaj   +1 more source

SGLT2 inhibitor protects cardiomyocytes against palmitate-induced lipotoxicity by increasing activation of AMPK and lipid oxidations

, 2022
Low doses of palmitates evoked lipotoxicity in cardiomyocytes. Although SGLT2 expression was less in myocardial cells, treatment of SGLT2 inhibitor dramatically reduced palmitate-induced expression levels of inflammatory cytokines, such as IL-1beta and ...
Lee, Han Byeol, Seo, Mi Hye, Choi, Sung-E, Lee, Nami, Kim, Dae Jung, Lee, Min Jeong, Kim, Tae Ho, Lee, Kwan-Woo, Moon, Hyun Uk, Kang, Yup, Han, Seung Jin   +10 more
core   +1 more source